COVID-19 Vaccine Demand and Pricing Concerns Shake Moderna, Pfizer, and BioNTech Stocks
TL;DR Summary
Moderna shares slumped to a nearly three-year low after the biotech firm expressed uncertainty about the demand for its COVID-19 vaccines, stating that it is too early to predict vaccination rates for the full year. The company reiterated its full-year guidance but warned that it couldn't accurately project the exact demand for its vaccines yet. This update follows Pfizer's decision to cut its outlook due to a lack of demand for COVID-19 products.
- Moderna Shares Slump Amid Concerns About COVID-19 Vaccine Demand Investopedia
- Pfizer trims expectations for 2023 with sales of COVID-19 vaccine, treatment, weaker than thought ABC News
- Price of lifesaving Covid-19 antiviral Paxlovid expected to rise next year, raising concerns about access AOL
- Why Pfizer And Moderna Are Suddenly Charging 500 Percent More For COVID Shots – OpEd Eurasia Review
- Moderna, BioNTech Leads Covid Sell-Off After Pfizer Slashes Outlook Investor's Business Daily
Reading Insights
Total Reads
0
Unique Readers
9
Time Saved
1 min
vs 2 min read
Condensed
74%
277 → 73 words
Want the full story? Read the original article
Read on Investopedia